Business Wire

Laboratory Studies Confirm the Effectiveness of BETADINE ® Gargle and Mouthwash Against COVID-19 Virus

Share

Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, has confirmed the effectiveness of BETADINE® Gargle and Mouthwash against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. BETADINE® is manufactured and distributed in Malaysia by Mundipharma.

BETADINE® Gargle and Mouthwash was tested for virucidal activity in two concentrations, undiluted (PVP-I 1% w/v) and at a 1:2 dilution (PVP-I 0.5% w/v) under established European (EN14476) methodology and standards. The testing demonstrated strong in-vitro virucidal activity, with the tested products killing 99.99% of the SARS-CoV-2 virus in just 15 seconds.

The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.

“Laboratory testing has shown that BETADINE® Gargle and Mouthwash is effective against COVID-19 and could contribute to our ongoing efforts to keep people and communities safe,” said Dr Pouya Hassandarvish, the Lead Investigator of the Study and the postdoctoral fellow researcher at TIDREC, University of Malaya.

“These results confirm our view that BETADINE® Gargle and Mouthwash, used appropriately and in conjunction with other preventative treatment options including PPE, could play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, Mundipharma CEO.

“It also provides the medical and dental community with a science-based assurance that they are using a product that is specifically studied against COVID-19,” he added.

Previously, BETADINE® antiseptic products containing Povidone-iodine (PVP-I) have been proven effective against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic range contains Povidone-iodine (PVP-I), which is effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals and homes.

About TIDREC

TIDREC serves as a focal point for national and international collaborative research for academic institutions and research industries in Malaysia. TIDREC also emphasizes on education and development of human skills. By advocating safe laboratory science, TIDREC aspires to be an internationally recognized centre of excellence in tropical infectious diseases research and education that serves the health needs of global communities.

TIDREC was the first research centre in the country to install fully certified modular biosafety level 2 & 3 laboratories for research involving highly virulent pathogens. TIDREC is also the only centre currently operating a mock biosafety level 3 training facility. The centre also houses the WHO Collaborating Centre for Arbovirus Reference & Research. The centre offer services such as drug screening, validation test for diagnostic kits and research collaboration on vector-borne diseases.

TIDREC mission is to advance knowledge by focusing on research in neglected tropical infectious diseases that have a potential impact on the global community.

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

About BETADINE®

The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections. Over the last few years, Mundipharma has expanded the BETADINE® range of products to include Povidone-iodine and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand hygiene. In-vitro and clinical studies have demonstrated that BETADINE® Povidone-iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.

®: BETADINE is a registered trademark of Mundipharma

Contact information

For further information please contact:

Alice George
Principal Consultant
AG Global Communications
A-13-4, Tiara Faber
456, Jalan Desa Utama
Taman Desa
58100 Kuala Lumpur
Malaysia
Email: alice.agcomm@gmail.com
Mobile: +60196008157

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xerox Launches ConnectKey-Enabled AltaLink Digital Workplace Assistant15.7.2020 18:47:00 CESTPress release

Xerox announced its new https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.office.xerox.com%2Fen-us%2Fmultifunction-printers%2Faltalink-c8100-series&esheet=52250531&newsitemid=20200715005746&lan=en-US&anchor=Xerox+AltaLink%26%23174%3B+C8100&index=1&md5=59e47e2191588f21b4da900931086697 Xerox AltaLink® C8100 and Xerox AltaLink B8100 Series multi-function printers (MFPs), that can better support today’s flexible work environment and help companies speed their digital transformation with access to the ConnectKey® ecosystem of apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005746/en/ The tablet-like user interface allows for easy, familiar interaction or the user can choose to print from their mobile devices. (Photo: Business Wire) In addition to its printing capabilities, the AltaLink 8100 series helps speed workplace digitization with ultra-fast scanning of up to 270 images per minute and Optical

Bureau Veritas Launches a New Solution to Improve Supply Chain Resilience15.7.2020 17:45:00 CESTPress release

Bureau Veritas, a world leader in testing, inspection and certification (TIC) services, is launching Supply-R, a solution designed to meet companies’ new challenges relating to supplier network reliability and ensuring business continuity in all circumstances. Organizations learned multiple lessons during the first half of 2020 on the resilience of global supply chains and their ability to face disruptions. There is an urgent need from many companies to reassess their supply chain risk, based on factual data from the field, to make sure that all elements are properly addressed, assessed and visible. Bruno Ferreyra, Executive Vice-President at Bureau Veritas, commented: "Economic globalization means supply chains include more suppliers and intermediaries than before, and they are scattered around the globe. This makes each step, process and stakeholder in the manufacturing chain harder to track. Our goal is to support businesses, mapping out their supply chains to give them complete con

VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors15.7.2020 17:40:00 CESTPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors. Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The first visit of this first subject, a few days after obtaining both ANSM1 approval and the favorable decision from the CPP2, marks the concrete launch of the REVERSE-IT study, the results of which are expected in mid-2022. We are right on schedule and are delighted to be able to enter the operational phase of this major study so quickly. We also welcome the enthusiasm and commitment of all the partner investigation centers." Dr Hans-Juergen WOERLE, Chief Scientific and Medical Off

Octapharma Reports Positive Data from octagam ® Usage in Critically Ill COVID-19 Patients15.7.2020 17:04:00 CESTPress release

Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group. The study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen. In critically ill COVID-19 patients, the cause of death often implicates an abnormal pulmonary immune response. This abnormal immune response is characterized by high levels of inflammatory markers, which are associated with poor clinical outcomes.1, 2 Acute respiratory distress syndrome (ARDS) and multiorgan failure are major causes of mortality in COVID-19 patients.3 High levels of pro-inflammatory cytokines and chemokines are part of a severe inflammatory response known as a “cytokine storm” which may cause multiple organ dysfunction and ARDS in criti

European Commission approves third nintedanib indication in pulmonary fibrosis 115.7.2020 15:34:00 CESTPress release

Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality simila

With U.S. Cotton Trust Protocol, Brands and Retailers Can Now Source U.S. Cotton with More Confidence15.7.2020 15:05:00 CESTPress release

Startingtoday, brands and retailers can join the U.S. Cotton Trust Protocol, a new system for responsibly grown cotton that will provide annual data for six areas of sustainability in line with the U.N. Sustainability Goals. This year-over-year data, available for the first time, will allow brands and retailers to better measure progress towards meeting sustainability commitments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005278/en/ (Graphic: Business Wire) “One of our goals in developing the Trust Protocol is to give brands and retailers greater confidence when including U.S. cotton in their sourcing mix,” said Ken Burton, Executive Director of the U.S. Cotton Trust Protocol. “Participating brands and retailers will now be able to demonstrate measurable progress in reducing their environmental footprint and in achieving sustainability targets.” The Trust Protocol underpins and verifies sustainability progress thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom